PDB Short entry for 1UZE HEADER METALLOPROTEASE 11-MAR-04 1UZE TITLE COMPLEX OF THE ANTI-HYPERTENSIVE DRUG ENALAPRILAT AND THE TITLE 2 HUMAN TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANGIOTENSIN CONVERTING ENZYME; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EXTRACELLULAR DOMAIN, RESIDUES 68-656; COMPND 5 SYNONYM: ACE-T, DIPEPTIDYL CARBOXYPEPTIDASE I, KININASE II; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 ORGAN: TESTIS; SOURCE 6 EXPRESSION_SYSTEM: CHINESE HAMSTER OVARY; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: CHO; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PLEN KEYWDS METALLOPROTEASE, ANGIOTENSIN CONVERTING ENZYME, INHIBITOR, KEYWDS 2 ENALAPRILAT, ZINC DEPENDANT PEPTIDASE, ANTI-HYPERTENSIVE KEYWDS 3 DRUG EXPDTA X-RAY DIFFRACTION AUTHOR R.NATESH,S.L.U.SCHWAGER,H.R.EVANS,E.D.STURROCK,K.R.ACHARYA REVDAT 3 24-FEB-09 1UZE 1 VERSN REVDAT 2 06-MAR-06 1UZE 1 REMARK REVDAT 1 16-JUL-04 1UZE 0 JRNL AUTH R.NATESH,S.L.U.SCHWAGER,H.R.EVANS,E.D.STURROCK, JRNL AUTH 2 K.R.ACHARYA JRNL TITL STRUCTURAL DETAILS ON THE BINDING OF JRNL TITL 2 ANTIHYPERTENSIVE DRUGS CAPTOPRIL AND ENALAPRILAT JRNL TITL 3 TO HUMAN TESTICULAR ANGIOTENSIN I-CONVERTING JRNL TITL 4 ENZYME JRNL REF BIOCHEMISTRY V. 43 8718 2004 JRNL REFN ISSN 0006-2960 JRNL PMID 15236580 JRNL DOI 10.1021/BI049480N REMARK 2 REMARK 2 RESOLUTION. 1.82 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.82 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99 REMARK 3 NUMBER OF REFLECTIONS : 58651 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING SET) : 0.188 REMARK 3 FREE R VALUE : 0.211 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 2.5 REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4662 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 456 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.2 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1UZE COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 11-MAR-04. REMARK 100 THE PDBE ID CODE IS EBI-14774. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 4.60 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SRS REMARK 200 BEAMLINE : PX14.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.488 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 58651 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.820 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 8.000 REMARK 200 R MERGE (I) : 0.08900 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 21.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.82 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.89 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.7 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.40600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 4.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): NULL REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): NULL REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.36000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 66.86500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.67500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 66.86500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.36000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.67500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LEU A 37 REMARK 465 VAL A 38 REMARK 465 THR A 39 REMARK 465 SER A 435 REMARK 465 GLU A 436 REMARK 465 GLY A 437 REMARK 465 GLY A 438 REMARK 465 TYR A 619 REMARK 465 ASN A 620 REMARK 465 TRP A 621 REMARK 465 THR A 622 REMARK 465 PRO A 623 REMARK 465 ASN A 624 REMARK 465 SER A 625 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASP A 40 CG OD1 OD2 REMARK 470 GLU A 64 CG CD OE1 OE2 REMARK 470 LYS A 117 CG CD CE NZ REMARK 470 SER A 298 OG REMARK 470 GLU A 303 CG CD OE1 OE2 REMARK 470 LYS A 307 CG CD CE NZ REMARK 470 ASP A 440 CG OD1 OD2 REMARK 470 GLN A 618 CA C O CB CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 463 CA - CB - CG ANGL. DEV. = 14.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 72 73.38 -172.34 REMARK 500 GLU A 123 -135.39 55.36 REMARK 500 LYS A 363 -35.93 -134.44 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 GLY A 2000 REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 ZN A 701 ZN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 EAL A3002 O2 REMARK 620 2 EAL A3002 O3 53.0 REMARK 620 3 HIS A 387 NE2 92.6 125.2 REMARK 620 4 GLU A 411 OE1 156.3 103.5 105.7 REMARK 620 5 HIS A 383 NE2 98.6 116.4 109.2 89.6 REMARK 620 N 1 2 3 4 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZN A 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 703 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 704 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GLY A2000 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EAL A3002 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1O86 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN REMARK 900 CONVERTING ENZYME IN COMPLEX WITH LISINOPRIL. REMARK 900 RELATED ID: 1O8A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN REMARK 900 CONVERTING ENZYME (NATIVE). REMARK 900 RELATED ID: 1UZF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN REMARK 900 CONVERTING ENZYME IN COMPLEX WITH CAPTOPRIL DBREF 1UZE A 37 625 UNP P22966 ACET_HUMAN 68 656 SEQRES 1 A 589 LEU VAL THR ASP GLU ALA GLU ALA SER LYS PHE VAL GLU SEQRES 2 A 589 GLU TYR ASP ARG THR SER GLN VAL VAL TRP ASN GLU TYR SEQRES 3 A 589 ALA GLU ALA ASN TRP ASN TYR ASN THR ASN ILE THR THR SEQRES 4 A 589 GLU THR SER LYS ILE LEU LEU GLN LYS ASN MET GLN ILE SEQRES 5 A 589 ALA ASN HIS THR LEU LYS TYR GLY THR GLN ALA ARG LYS SEQRES 6 A 589 PHE ASP VAL ASN GLN LEU GLN ASN THR THR ILE LYS ARG SEQRES 7 A 589 ILE ILE LYS LYS VAL GLN ASP LEU GLU ARG ALA ALA LEU SEQRES 8 A 589 PRO ALA GLN GLU LEU GLU GLU TYR ASN LYS ILE LEU LEU SEQRES 9 A 589 ASP MET GLU THR THR TYR SER VAL ALA THR VAL CYS HIS SEQRES 10 A 589 PRO ASN GLY SER CYS LEU GLN LEU GLU PRO ASP LEU THR SEQRES 11 A 589 ASN VAL MET ALA THR SER ARG LYS TYR GLU ASP LEU LEU SEQRES 12 A 589 TRP ALA TRP GLU GLY TRP ARG ASP LYS ALA GLY ARG ALA SEQRES 13 A 589 ILE LEU GLN PHE TYR PRO LYS TYR VAL GLU LEU ILE ASN SEQRES 14 A 589 GLN ALA ALA ARG LEU ASN GLY TYR VAL ASP ALA GLY ASP SEQRES 15 A 589 SER TRP ARG SER MET TYR GLU THR PRO SER LEU GLU GLN SEQRES 16 A 589 ASP LEU GLU ARG LEU PHE GLN GLU LEU GLN PRO LEU TYR SEQRES 17 A 589 LEU ASN LEU HIS ALA TYR VAL ARG ARG ALA LEU HIS ARG SEQRES 18 A 589 HIS TYR GLY ALA GLN HIS ILE ASN LEU GLU GLY PRO ILE SEQRES 19 A 589 PRO ALA HIS LEU LEU GLY ASN MET TRP ALA GLN THR TRP SEQRES 20 A 589 SER ASN ILE TYR ASP LEU VAL VAL PRO PHE PRO SER ALA SEQRES 21 A 589 PRO SER MET ASP THR THR GLU ALA MET LEU LYS GLN GLY SEQRES 22 A 589 TRP THR PRO ARG ARG MET PHE LYS GLU ALA ASP ASP PHE SEQRES 23 A 589 PHE THR SER LEU GLY LEU LEU PRO VAL PRO PRO GLU PHE SEQRES 24 A 589 TRP ASN LYS SER MET LEU GLU LYS PRO THR ASP GLY ARG SEQRES 25 A 589 GLU VAL VAL CYS HIS ALA SER ALA TRP ASP PHE TYR ASN SEQRES 26 A 589 GLY LYS ASP PHE ARG ILE LYS GLN CYS THR THR VAL ASN SEQRES 27 A 589 LEU GLU ASP LEU VAL VAL ALA HIS HIS GLU MET GLY HIS SEQRES 28 A 589 ILE GLN TYR PHE MET GLN TYR LYS ASP LEU PRO VAL ALA SEQRES 29 A 589 LEU ARG GLU GLY ALA ASN PRO GLY PHE HIS GLU ALA ILE SEQRES 30 A 589 GLY ASP VAL LEU ALA LEU SER VAL SER THR PRO LYS HIS SEQRES 31 A 589 LEU HIS SER LEU ASN LEU LEU SER SER GLU GLY GLY SER SEQRES 32 A 589 ASP GLU HIS ASP ILE ASN PHE LEU MET LYS MET ALA LEU SEQRES 33 A 589 ASP LYS ILE ALA PHE ILE PRO PHE SER TYR LEU VAL ASP SEQRES 34 A 589 GLN TRP ARG TRP ARG VAL PHE ASP GLY SER ILE THR LYS SEQRES 35 A 589 GLU ASN TYR ASN GLN GLU TRP TRP SER LEU ARG LEU LYS SEQRES 36 A 589 TYR GLN GLY LEU CYS PRO PRO VAL PRO ARG THR GLN GLY SEQRES 37 A 589 ASP PHE ASP PRO GLY ALA LYS PHE HIS ILE PRO SER SER SEQRES 38 A 589 VAL PRO TYR ILE ARG TYR PHE VAL SER PHE ILE ILE GLN SEQRES 39 A 589 PHE GLN PHE HIS GLU ALA LEU CYS GLN ALA ALA GLY HIS SEQRES 40 A 589 THR GLY PRO LEU HIS LYS CYS ASP ILE TYR GLN SER LYS SEQRES 41 A 589 GLU ALA GLY GLN ARG LEU ALA THR ALA MET LYS LEU GLY SEQRES 42 A 589 PHE SER ARG PRO TRP PRO GLU ALA MET GLN LEU ILE THR SEQRES 43 A 589 GLY GLN PRO ASN MET SER ALA SER ALA MET LEU SER TYR SEQRES 44 A 589 PHE LYS PRO LEU LEU ASP TRP LEU ARG THR GLU ASN GLU SEQRES 45 A 589 LEU HIS GLY GLU LYS LEU GLY TRP PRO GLN TYR ASN TRP SEQRES 46 A 589 THR PRO ASN SER HET ZN A 701 1 HET CL A 703 1 HET CL A 704 1 HET GLY A2000 4 HET EAL A3002 25 HETNAM ZN ZINC ION HETNAM CL CHLORIDE ION HETNAM GLY GLYCINE HETNAM EAL 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL] HETNAM 2 EAL AMINO}PROPANOYL)-L-PROLINE HETSYN EAL ENALAPRILAT INHIBITOR FORMUL 2 ZN ZN 2+ FORMUL 3 CL 2(CL 1-) FORMUL 5 GLY C2 H5 N O2 FORMUL 6 EAL C18 H24 N2 O5 FORMUL 7 HOH *456(H2 O1) HELIX 1 1 ASP A 40 THR A 71 1 32 HELIX 2 2 THR A 74 ARG A 100 1 27 HELIX 3 3 ASP A 103 LEU A 107 5 5 HELIX 4 4 ASN A 109 GLN A 120 1 12 HELIX 5 5 LEU A 122 LEU A 127 5 6 HELIX 6 6 PRO A 128 ALA A 149 1 22 HELIX 7 7 PRO A 163 SER A 172 1 10 HELIX 8 8 LYS A 174 ALA A 189 1 16 HELIX 9 9 ALA A 189 LEU A 194 1 6 HELIX 10 10 PHE A 196 ASN A 211 1 16 HELIX 11 11 ASP A 215 SER A 222 1 8 HELIX 12 12 MET A 223 GLU A 225 5 3 HELIX 13 13 SER A 228 LEU A 240 1 13 HELIX 14 14 LEU A 240 GLY A 260 1 21 HELIX 15 15 TRP A 283 ASN A 285 5 3 HELIX 16 16 ILE A 286 VAL A 291 1 6 HELIX 17 17 ASP A 300 GLN A 308 1 9 HELIX 18 18 THR A 311 LEU A 326 1 16 HELIX 19 19 PRO A 332 SER A 339 1 8 HELIX 20 20 ASN A 374 TYR A 394 1 21 HELIX 21 21 PRO A 398 ARG A 402 5 5 HELIX 22 22 ASN A 406 SER A 422 1 17 HELIX 23 23 THR A 423 LEU A 430 1 8 HELIX 24 24 SER A 439 ASP A 473 1 35 HELIX 25 25 ASN A 480 GLY A 494 1 15 HELIX 26 26 PHE A 506 LYS A 511 5 6 HELIX 27 27 TYR A 520 ALA A 541 1 22 HELIX 28 28 PRO A 546 CYS A 550 5 5 HELIX 29 29 SER A 555 LYS A 567 1 13 HELIX 30 30 PRO A 573 GLY A 583 1 11 HELIX 31 31 ALA A 589 HIS A 610 1 22 SHEET 1 AA 2 THR A 150 CYS A 152 0 SHEET 2 AA 2 CYS A 158 GLN A 160 -1 O LEU A 159 N VAL A 151 SHEET 1 AB 2 ILE A 270 PRO A 271 0 SHEET 2 AB 2 LEU A 495 CYS A 496 1 N CYS A 496 O ILE A 270 SHEET 1 AC 2 SER A 355 ASP A 358 0 SHEET 2 AC 2 PHE A 365 LYS A 368 -1 O ARG A 366 N TRP A 357 SSBOND 1 CYS A 152 CYS A 158 1555 1555 2.03 SSBOND 2 CYS A 352 CYS A 370 1555 1555 2.03 SSBOND 3 CYS A 538 CYS A 550 1555 1555 2.03 LINK ZN ZN A 701 O2 EAL A3002 1555 1555 2.66 LINK ZN ZN A 701 O3 EAL A3002 1555 1555 2.02 LINK ZN ZN A 701 NE2 HIS A 387 1555 1555 2.05 LINK ZN ZN A 701 OE1 GLU A 411 1555 1555 1.89 LINK ZN ZN A 701 NE2 HIS A 383 1555 1555 2.10 CISPEP 1 GLU A 162 PRO A 163 0 0.19 SITE 1 AC1 4 HIS A 383 HIS A 387 GLU A 411 EAL A3002 SITE 1 AC2 4 ARG A 186 TRP A 485 TRP A 486 ARG A 489 SITE 1 AC3 6 TYR A 224 PRO A 407 PRO A 519 ILE A 521 SITE 2 AC3 6 ARG A 522 HOH A2172 SITE 1 AC4 7 VAL A 379 ASP A 415 ASP A 453 LYS A 454 SITE 2 AC4 7 PHE A 527 HOH A2334 EAL A3002 SITE 1 AC5 18 GLN A 281 HIS A 353 ALA A 354 HIS A 383 SITE 2 AC5 18 GLU A 384 HIS A 387 GLU A 411 LYS A 511 SITE 3 AC5 18 PHE A 512 HIS A 513 VAL A 518 TYR A 520 SITE 4 AC5 18 TYR A 523 ZN A 701 GLY A2000 HOH A2281 SITE 5 AC5 18 HOH A2455 HOH A2456 CRYST1 56.720 85.350 133.730 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017630 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011716 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007478 0.00000